Private equity firm Lone Star Funds has agreed to acquire the capsules and health ingredients division of Swiss life sciences group Lonza in a transaction valuing the business at CHF2.3bn (around $3bn), according to a report by Reuters.
The deal will see Lone Star take control of the unit while Lonza retains a 40% minority interest. The company will receive approximately CHF1.7bn in upfront proceeds, with total undiscounted proceeds from the transaction expected to reach at least CHF3bn.
The divestment follows Lonza’s decision in late 2024 to explore strategic options for the business as part of a wider effort to streamline operations and focus on its core contract drug development and manufacturing activities.
For Lone Star, the acquisition represents another investment in the healthcare and life sciences sector, acquiring a business focused on capsule manufacturing and health ingredients used across pharmaceutical and nutrition markets.
The transaction is expected to complete in the second half of 2026, subject to customary closing conditions.
